{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:21:13Z","timestamp":1792023673250,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rmed.2025.108343","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:13:59Z","timestamp":1757096039000},"page":"108343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-4544","authenticated-orcid":false,"given":"Philipp","family":"Suter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7668-286X","authenticated-orcid":false,"given":"Robert","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-8266","authenticated-orcid":false,"given":"Rory","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-2014","authenticated-orcid":false,"given":"Brian","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.rmed.2025.108343_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082670","article-title":"Role of Type2 inflammatory biomarkers in chronic obstructive pulmonary disease","volume":"9","author":"Oishi","year":"2020","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108343_bib2","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","article-title":"Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease","volume":"141","author":"Yun","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.rmed.2025.108343_bib3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","article-title":"Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General population study","volume":"193","author":"Vedel-Krogh","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108343_bib4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"24","key":"10.1016\/j.rmed.2025.108343_bib5","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108343_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.rmed.2025.108343_bib7","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108343_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.108343_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.rmed.2025.108343_bib10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108343_bib11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.rmed.2025.108343_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.rmed.2025.108343_bib13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108343_bib14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1164\/rccm.200408-1054OC","article-title":"Exacerbations and time spent outdoors in chronic obstructive pulmonary disease","volume":"171","author":"Donaldson","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108343_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1465-9921-10-59","article-title":"Efficacy of salmeterol\/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study","volume":"10","author":"Jenkins","year":"2009","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108343_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107506","article-title":"Impact of COPD on mortality: an 8-year observational retrospective healthcare claims database cohort study","volume":"222","author":"Vogelmeier","year":"2024","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108343_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/COPD.S438893","article-title":"Risk of death and cardiovascular events following an exacerbation of COPD: the EXACOS-CV US study","volume":"19","author":"Daniels","year":"2024","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"11","key":"10.1016\/j.rmed.2025.108343_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Cataluna","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2025.108343_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107682","article-title":"Correlation of fractional exhaled nitric oxide (FeNO) and clinical outcomes in patients with chronic obstructive pulmonary disease: a prospective cohort study","volume":"229","author":"Keeratichananont","year":"2024","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108343_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/all.15901","article-title":"Effect of dupilumab on sputum eosinophils in patients with moderate-to-severe asthma","volume":"79","author":"Svenningsen","year":"2024","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.rmed.2025.108343_bib21","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(18)30275-3","article-title":"Anti-interleukin 13 for asthma: stick or twist?","volume":"6","author":"Lipworth","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108343_bib22","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.rmed.2025.108343_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108343_bib24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaci.2024.11.024","article-title":"Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthma","volume":"155","author":"Stewart","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.rmed.2025.108343_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-2600(25)00044-X","article-title":"Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Christenson","year":"2025","journal-title":"Lancet Respir. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125004068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125004068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:06:28Z","timestamp":1761116788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125004068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"alternative-id":["S0954611125004068"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108343","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108343"}}